VELscope’s fluorescence technology aids in the early visualization of mucosal diseases and enhances effective oral mucosal screening
VELscope® is a revolutionary hand-held device that provides dentists and hygienists with an easy-to-use adjunctive mucosal examination system for the early detection of abnormal tissue. The patented VELscope technology platform was developed in collaboration with the British Columbia Cancer Agency and MD Anderson Cancer Center, with funding provided in part by the NIH. It is based on the direct visualization of tissue fluorescence and the changes in fluorescence that occur when abnormalities are present.
The VELscope Handpiece emits a safe blue light into the oral cavity, which excites the tissue from the surface of the epithelium through to the basement membrane (where premalignant changes typically start) and into the stroma beneath, causing it to fluoresce. The clinician is then able to immediately view the different fluorescence responses to help differentiate between normal and abnormal tissue. In fact, VELscope is the only non-invasive adjunctive device clinically proven to help discover occult oral disease.
Typically, healthy tissue appears as a bright apple-green glow while suspicious regions are identified by a loss of fluorescence, which thus appear dark.
VELscope provides a more effective oral cancer screening protocol with immediate benefits for the patient, clinician and practice
When used as an adjunctive aid in combination with traditional oral cancer examination procedures, VELscope facilitates the early discovery and visualization of mucosal abnormalities prior to surface exposure that may be, or may lead to oral cancer. In one or two minutes, with no rinses or stains required, a VELscope examination helps oral healthcare professionals assure their patients that the standard of care for oral mucosal screening has been utilized. Through the CDT code D0431, an increasing number of insurance companies are recognizing VELscope as an adjunctive screening device. VELscope combines minimal per-patient costs with more effective screening.
.
